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Abstract
The goal of this research was to express and purify Cellular Retinoic Acid Binding
Protein Type 1 (CRABP1). CRABP1 binds to retinoic acid in the cell and shuttles the retinoic
acid from one area in the cell to another. The overproduction of CRABP1 appears to be
problematic because it can sequester the retinoic acid and prevent it from regulating gene
expression. Previous studies have shown that increased levels of CRABP1 can result in
tumor-promoting activity and disruption of lipid biology in the cell. Our objective was to
express this protein in an inducible bacterial system, so that we could purify the protein
and characterize its functions in vitro. Initial work to express the protein using a cloning
vector and inducible promoter was unsuccessful; however, we were able to clone the
crabp1 gene into other expression vectors and will test transformants for inducible
expression in future experiments.
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Introduction
One in eight women will contract invasive breast cancer over the course of her
lifetime. In the United States alone, it is estimated that in 2020, approximately 276,480
women will be diagnosed with invasive breast cancer, plus another 48,530 women will be
diagnosed with non-invasive breast cancer. Breastcancer.org, 2019) It is estimated that 30%
of cancers diagnosed in women this year will be breast cancer. Besides skin cancer, breast
cancer is the most come type of cancer among women (“Breastcancer.org, 2020) These
startling numbers beg the question, what more can be done? With one of the highest
incidences, more research needs to be done on breast cancer to find a cure.
Cancer often arises from mutations in the cellular genome. This mutated genetic
information can lead to the production of cell cycle proteins that either lose specific
functions or have altered functions, and these mutations may result in the rapid
overgrowth and division of cells. Specifically, there are two groups of genes that express
cell cycle proteins. The first group is called proto-oncogenes. These are genes that produce
proteins that encourage cell proliferation and inhibit cell death (Does, 2004). The other
group is tumor suppressors. These genes produce proteins that prevent cell proliferation
and induce cell death. These two groups work in opposition to regulate cell growth. One
way in which cells become cancerous is with the mutation of a proto-oncogene into an
oncogene, causing cell growth to accelerate without control. Mutations of proto-oncogenes
are usually found to be dominant. This means that only one out of the two copies of the
gene within the cell needs to be mutated in order to get mutated function. If these
mutations occur in germ line cells, egg cells, or sperm cells, they will get passed down to
offspring (Does, 2004).
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Mutations could also occur in tumor suppressor genes. Mutations in these genes
cause a loss of function of the resulting proteins. This means that these proteins are no
longer able to inhibit cell proliferation, and the proto-oncogenes or oncogenes are able to
cause mass cell divisions without the regulation of the tumor suppressors (Does, 2004).
These mutations can also be hereditary, but they are recessive so the mutation would have
to be present in both copies of the gene to cause an alteration in function. This could
happen by the first mutated copy being inherited and the second one mutating itself, or
both could mutate without hereditary influence. BReast CAncer 1 and BReast CAncer 2
(BRCA1 and BRCA2) gene mutations are a common example of a hereditary mutation that
can lead to breast cancer (Does, 2004). Both of these genes are tumor suppressors. BRCA1
plays a role in cell cycle control, while BRCA2 is involved in DNA repair processes. These
are both crucial functions that when disabled lead to breast cancer (Does, 2004).
Lastly, mutations can occur in DNA repair genes. Mutations in a cell’s DNA may arise
spontaneously from ultraviolet radiation, ionizing radiation, chemical damage, or mistakes
made during DNA replication. Without functional DNA repair proteins, these gene defects
could lead to an increased risk of developing cancer (Does, 2004).
Although mutations to proto-oncogenes, tumor suppressors, and the DNA repair
machinery can lead to breast cancer, other proteins may also be associated with breast
cancer tumorigenesis. One such protein is Cellular Retinoic Acid Binding Protein 1
(CRABP1). CRABP1’s normal function is to shuttle retinoic acid, a vitamin A derivative,
around the cells (Connolly et al., 2013). Retinoic acid plays an important part in cell
differentiation, regulation of growth, and apoptosis (Connolly et. al., 2013). It has been
observed that the overexpression of CRABP1 has been associated with breast cancer
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incidence (Liu et. al., 2015). In this section I will discuss the function of retinoic acid, the
role of CRABP1, how CRABP1 is thought to be related to breast cancer, and how we hope to
further investigate the role of this protein in disease progression.
CRABP1 binds to retinoic acid, which is a metabolite of Vitamin A. Vitamin A is a
very important vitamin for human survival and is required for development in the embryo
through adulthood. In fact, not getting enough vitamin A can lead to vitamin A deficiency
(VAD), and this can cause a wide variety of defects including intellectual and physical
disabilities. In adults, a lack in vitamin A can impair things like vision, reproduction, and
the immune system (Tanoury et al., 2013). Retinoic acid and other retinoid derivatives
regulate processes like cell proliferation, cell differentiation, apoptosis, the inflammatory
response, embryo growth, and functions in the nervous and immune systems (Napoli et al.,
2017). This means that retinoic acid and its derivatives play a key role in stopping the
overgrowth of cells and keep the cell cycle in check. For this reason, there has been
extensive research done on retinoic acid for cancer treatment. The Food and Drug
Administration has approved the use of retinoic acid as a leukemia and lymphoma therapy
(Chen et al., 2014). Retinoic acid has the ability to inhibit tumor growth, the formation of
new blood vessels, and metastasis (Chen et al., 2014).
Many proteins are involved in the transport of retinoids throughout the cell,
including cellular retinol binding proteins 1 and 2 (CRBP1 and CRBP2), CRABP2, and
FABP5 (fatty acid binding protein 5). These proteins shuttle retinoids from one cellular
compartment to another. CRBP1 carries retinol and retinal in various cell types, while
CRBP2 also carries retinol and retinal, but is specific to cells of the small intestine. CRABP2
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carries retinoic acid isomers to the skin, uterus, and ovaries. FABP5 shuttles long-chain
fatty acids and retinoic acid in many types of cells, but specifically liver cells (Napoli et al.,
2017).
Because retinoic acid is a largely hydrophobic molecule, it is not very soluble in
aqueous compartments of the cell. In order for the retinoic acid to travel through the cell, it
binds to CRABP1 and is shuttled around within the cell. CRABP1 is capable of
accommodating retinoic acid in a non-polar binding pocket (Napoli et al., 2017). The
CRABP1 protein is structured like a barrel (Figure 1). It has hydrophobic amino acids
facing the interior of the barrel where the hydrophobic tail of the retinoic acid molecule
binds. The outside of the barrel has polar amino acids lining it so that it can interact with its
aqueous surroundings. The carboxylate side of the retinoic acid molecule hydrogen bonds
to the polar amino acids in the binding pocket.
CRABP1 has two hypothesized roles. First, CRABP1 has a high affinity for
cytoplasmic retinoic acid. Researchers hypothesized that CRABP1 decreases the
concentration of available retinoic acid for the nucleus while also deactivating it. When
CRABP1’s expression was altered alterations and mutations were executed, researchers
observed that high concentrations of CRABP1 caused cells have a decrease in
responsiveness to retinoic acid. That is, cells were less affected by retinoic acid as a gene
expression regulator with an increase of cellular levels of CRABP1 (Wei, 2012). Another
theory proposed for CRABP1’s function is that it aids in the conversion of retinoic acid into
other, more polar, derivatives that help regulate gene expression by binding to retinoic acid
receptors in the nucleus (Wei, 2012). This pathway is not fully understood, but when
cellular levels of CRABP1 were increased in one type of cell it caused an increase in the
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conversion of retinoic acid into its other derivatives. This could mean CRABP1 is at least
partly responsible for the modification of retinoic acid in cells (Wei, 2012).
To further test the importance of CRABP1, researchers disabled the gene in young,
developing mice. These young mice then died. Contradictory to this, when CRABP1 was
disabled in normal adult mice, few changes were seen in the health of the mice(Wei, 2012).
It was hypothesized, however, that the adult mice may have had and alternative
mechanism for the transportation and regulation of retinoic acid and its pathway (Wei,
2012). This could suggest that CRABP1, which we know shuttles retinoic acid into the cells,
is needed much more in developing organisms.
Researchers also found that CRABP1 promotes pregnancy-associated breast cancer
and have hypothesized that changes in glandular structure during the stages of pregnancy,
specifically during lactation, may have an important role in pregnancy-associated breast
cancer (McCready et al., 2014). Mammary adipose stromal cells were isolated from mice at
different stages of mammary development: post-pubertal, pregnancy, lactation, involution
(remodeling of the mammary gland back to its pre pregnant state), and regression. It was
found that ASCs that were acquired during lactation (ASC-Ls), but not other stages of
mammary development, promoted the growth of carcinoma cells (McCready et al., 2014).
Upon comparing gene expression of these cells to the cells in other developmental stages, it
was also determined that the CRABP1 gene was more highly expressed in ASC-Ls compared
to ASCs at other developmental stages. Inhibition of crabp1 expression in ASC-Ls restored
its ability to accumulate lipids, and incubation of these inhibited cells with carcinoma cells
resulted in smaller, slower growing tumor cells. These findings suggest that CRABP1
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overexpression in ASC-Ls has some association with the onset or progression of pregnancyassociated breast cancer (McCready et al., 2014).
From the experiments described above, there appears to be a link between the
expression of CRABP1 and breast cancer. The relationships between CRABP1, lipid binding
and lipid sequestration in breast cancer is unclear. In an effort to understand CRABP1’s
function in these processes more completely, our research objective was to conduct
biochemical assays with purified CRABP1 protein. This thesis discusses our approach to
express CRABP1 and to clone the gene into several alternative expression plasmids.
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Methods
Expression of CRABP1
A pBlueScript (pBS) plasmid containing the crabp1 gene was obtained from the
Tabin Laboratory at Harvard Medical School (Boston, MA). The crabp1 gene is under the
control of a lac operator, and its expression can be induced in the presence of isopropyl βD-1-thiogalactopyranoside (IPTG). The plasmid was transformed into DH5a cells (see
Table 1 for antibiotic resistance), and a mini prep of the cells was done to yield a
concentrated amount of the CRABP1 plasmid DNA. Upon completion of the miniprep, the
concentration was measured.
The plasmid was then transformed into BL21(DE3) cells, cells that typically yield
large amounts of expressed protein. To induce the expression of CRABP1 in these cells, an
overnight culture of BL21(DE3) cells in Luria broth (LB) was first made. Overnight cultures
were made by using a sterile flask of LB broth (100mL). 100 μL of ampicillin (100 mg/ml)
was put into the flask. A sterile inoculating loop was used to pick up multiple colonies from
the respective plated culture and inserted into the flask of LB broth. The flask was then put
in a shaking incubator at 37°C at 200 rpm for about 12 hours. A sample was taken from this
culture and diluted to a ratio of 1:100 in fresh media (100 mL). This new sample grew to an
optical density (OD600) of approximately 0.5. Once the sample reached optimum density, 1
mL of 1 mM IPTG was added to the media to induce gene expression, and the cells were
induced at 25°C. Four 1-mL samples were taken: (1) uninduced sample (i.e., before IPTG
was added), (2) a sample take 3 hours after the induction of expression, (3) a sample taken
6 hours after the induction of expression, and (4) a sample of the culture after the
expressed was induced overnight. The samples were centrifuged (discarding all
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supernatant), and 100μL of 2x SDS buffer was added to each sample. Because the ODs of all
the samples were the same, the same amount of buffer was added to each sample to ensure
the same concentration of cell contents material per sample. These samples were heated at
95°C for 15 minutes, vortexing occasionally to lyse the cells. Next, the samples were
centrifuged for 10 minutes, and only the supernatant was saved. These samples were then
used to run two 15% polyacrylamide gels: one gel for Coomassie staining and another gel
for a Western blot. For gels that were transferred for a Western blot, the gel was
transferred onto nitrocellulose membrane using a Mini-Vertical PAGE/Blotting System
(Bio-Rad). The gels were transferred for 45 minutes at 100 V. The membrane was placed in
a cassette box with a blocking solution made with 5 g dry milk, 100mL Tris-Buffer Saline
(TBS), and 100 μL of Tween. This was incubated on a rocker at 15°C for 45 minutes. Next,
the membrane was rinsed three times with TBS. Then, the primary antibody solution was
added, which contained 10 mL TBS, 10 μL of Tween and 5 μL of primary mouse antibody
for a 1:2000 dilution ratio This was incubated on a rocker at 15°C for at least 1 hour and
sometimes overnight. After incubation with primary antibody, mouse antibody, the
membrane was rinsed with TBS-T three times. The secondary antibody solution was made
with 10 mL of TBS-T, 0.5 g dry milk and 2 μL of anti-mouse secondary antibody. This
secondary antibody solution was added and incubated on a rocker at 15°C for at least one
hour. The secondary antibody was then removed. It was then rinsed three times with TBS
and washed for one hour in TBS on a rocker at 15°C. The blot was then developed by
adding 700 μL of Luminol Enhancer and 700 μL of Peroxide Solution and visualized on the
GelDoc.
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Optimization of Protein Expression Using Glucose and pLysS
Two different variations of protein expression were also attempted to halt the leaky
expression if CRABP1 using the same plasmid. The first method was inducing the
expression of CRABP1 in the presence of glucose. For expression in the presence of
glucose, we conducted this experiment as described above except in the presence of 0%,
0.5%, 1%, and 2% glucose. From each culture, two samples were taken: (1) an uninduced
sample and (2) a sample taken 3 hours after induction. The other method used was to
induce expression in the presence of lysozyme. This was done using BL21(DE3) cells that
contain a pLysS plasmid that expresses T7 lysozyme that inhibits expression of inducible
genes prior to adding IPTG. Samples taken were again used to run two protein gels per test,
using one for Coomassie staining and one for a Western blot.

Subcloning crabp1
Next, we obtained three different expression vectors with the aim of cloning the
crabp1 gene into these vectors. The expression vectors that we used were pET15b, pRSF,
and pRSF Duet. The pET15-b and pRSF Duet include a His6 affinity tag that can be added to
the expressed protein. This His6 affinity tag can be used later during the protein
purification process using affinity chromatography. The cloning process involved multiple
steps: polymerase chain reaction (PCR) to amplify the gene of interest using vector-specific
primers, gel purification of the PCR products, restriction digest of the amplified crabp1
gene and the vectors of interest using the appropriate restriction enzymes, gel purification
of the digested products, ligation of the digested vector and crabp1 gene, and
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transformation of the ligated vector and gene into DH5⍺ cells. Any positive transformants
were tested through screening via colony PCR.
First, PCR was used to amplify crabp1 present in the plasmid template. In a PCR
tube, the following items were added: 2 μL of template DNA, 5 μL 10x Taq Buffer, with 4 μL
MgCl2, 1 μL dNTP mix, 2.5 μL forward primer, 2.5 μL reverse primer, 0.2 μL Taq DNA
polymerase, and 32.8 μL sterile water. A control was made by replacing the template DNA
with sterile water. A standard PCR protocol was used. PCR primers were made to contain
restriction enzyme sites that corresponded to each vector (Table 1).
The PCR products were then visualized using agarose gel electrophoresis. The bands
from the gel electrophoresis that corresponded to the molecular weight of the crabp1 PCR
product were then gel purified using a Wizard SV Gel and PCR Clean-Up System (Promega).
This was followed by a restriction digest using the proper restriction enzymes specific to
each vector. Both the crabp1 gene and vectors were digested. Each was combined with 1 uL
of each desired restriction enzyme, 3 μL of CutSmart, and the remaining volume was
deionized water (30 μL total volume). This mixture was put in a 37°C bath for at least one
hour.
The digests were again run on agarose gels using the same gel electrophoresis
protocol from the PCR gel electrophoresis, and the resulting bands from the digested
crabp1 genes and digested vectors were then gel purified. Next, crabp1 was ligated into
each of the vectors in a series of experiments. To insert the crabp1 gene into the desired
vector, different ratios of the gene and desired vector were used and subsequently
combined with DNA ligase. The ratios included: a 1:1 plasmid to insert ratio, a 3:5 plasmid
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to insert ratio, and a 1:7 plasmid to insert ratio. The tubes were then incubated at room
temperature for at least two hours.
To see if the ligations were successful, each ligation reaction was transformed into
DH5⍺ cells. The cells were plated on LB plates with proper antibiotic resistance (see table
1). Along with plating the experimental ligations, positive and negative control ligations
were also plated. Positive-control ligations were made by using an uncut vector, and
negative controls were made using digested vectors without an added crabp1 gene. Any
colonies that grew on the plates were tested via colony PCR to determine if the gene of
interest was present. Colony PCR is performed by picking colonies that grew on the
resulting plated cultures with a small pipette tip and inserting a part of the colony into a
small sample of hot water for 10 minutes. This sample is then used as the “DNA” sample for
the previously mentioned PCR protocol.
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Results
The purpose of these experiments was to overexpress and purify CRABP1. To start
this, IPTG was added to a liquid culture of BL21(DE3) cells transformed with the pBS
crabp1 plasmid in order to induce expression of CRABP1. A Western blot showing the
expression of the CRABP1 protein is shown in Figure 2 with a single band observed at
approximately 16 kDa, the presumed molecular weight of the CRABP1 protein. As the
induction time increases, the CRABP1 bands become lighter and lighter. Though the
function of IPTG is to induce expression, the highest expression appears to occur before it
is added. It is hypothesized that the CRABP1 protein is produced before induction and is
degrading over time.
Because there was no increase or overexpression of CRABP1, the experiment was
repeated with the addition of glucose. Different concentrations of a glucose solution (0.5%,
1%, and 2% glucose) were added to liquid cultures with the goal of inhibiting leaky
expression of the CRABP1 protein. Two protein gels were run: one for a Coomassie stain
(Figure 3) and one for a Western blot (Figure 4). In Figure 3, no discernable differences
could be observed in the Coomassie gel when comparing expression before and after
induction. In the lanes with 0.5%, 1%, and 2% glucose concentration, the overall protein
expression of the cells decreases from pre to post induction. Since anti-CRABP1 from mice
was used again and the mass of CRABP1 is 16 kDa, it can be assumed that the protein in the
bands of the western blot is CRABP1. Similarly to Figure 2, pre-induction saw more
expression than post-induction. Since glucose is supposed to prevent leaky expression,
there should be very little to no CRABP1 present in the pre-induction lanes.
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BL21(DE3) cells with an added pLysS plasmid, which expresses lysozyme in order
to inhibit RNA polymerase before the cells are induced with IPTG, were induced with IPTG.
Samples from before and 3 hours after induction were taken and run on an SDS-PAGE gel.
Figure 5 shows Coomassie stained protein gel with the uninduced in lane 2 and 3 hours
post induction in lane 3. There was little change in protein expression from before to after
induction.
When inducing with different forms of leaky expression inhibition failed to show an
increase in expression, the crabp1 gene was subcloned into new plasmids in order to see if
those might work better for expression. Our objective was to subclone the crabp1 gene into
three new vectors: pET-15b, pRSF-1 and pRSF-Duet.
The crapb1 gene was amplified by PCR using primers that had specific restriction
enzyme sites that corresponded to the different plasmid restriction enzyme sites into
which we hoped to insert the gene. Figure 6 shows the PCR products of crabp1 with pET15b and pRSF-1 specific primers, on an agarose gel. For lanes 2-7, there were bright bands
below 500 base pairs, assumed to be crabp1. Figure 7 shows the PCR product of crabp1
using primers specific for the pET-Duet vector. Lanes 2-4 contain the PCR product, which
all show crabp1 sized bands.
After the presumed crabp1 DNA bands were gel purified, the crabp1 and vectors
were digested with their corresponding restriction enzymes. Figure 8 displays the results
of the restriction digest done on the pET-Duet and pRSF-1 plasmids, as well as the crabp1
PCR product. Figure 9 shows the restriction of pET-15b and the crabp1 PCR product. The
pET-Duet digestion did not yield a significant amount of digested vector, even when
concentrations of vector were increased in the digest reactions (Figure 8). For this reason,
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we focused our subcloning efforts on the pRSF-1 and pET-15b vectors from this point
forward.
After the pRSF-1 and pET-15b vectors and crabp1 were successfully digested with
their respective restriction enzymes, the samples were gel purified, ligated, and
transformed into DH5α cells. The ligation of crabp1 into pET-15b was not successful, as no
plated cultures grew. The plated cultures of the ligation of crabp1 did accumulate colonies
on all of the plates. Figure 12 shows the results of the colony PCR of crabp1 ligated into
pRSF-1 from the transformed DH5α cells. Lanes 2-7 (gel on the left) and lanes 2-7 (gel on
the right) show faint bands right below the 500 base-pair mark, thought to be crabp1. The
positive and negative control lanes did not show any bands corresponding to crabp1.
Discussion
The goal of this research was to express and purify a recombinant form of the
CRABP1 protein with the objective of gaining a better understanding of the biochemistry of
the protein.
The first objective to be completed was to express CRABP1 in BL21(DE3) cells using
IPTG to induce its expression. When IPTG was added to the BL21(DE3) cells containing the
pBS plasmid encoding the crabp1 gene, the expression of CRABP1 decreased, as shown in
the Western blot (Figure 2). The bands were observed at a molecular weight between 15
and 16 kDa, which is consistent with the molecular weight of the CRABP1 protein, 15.556
kDa. However, it was expected that protein expression would increase upon induction and
that we would observe darker bands post-expression, indicative of more protein being
produced in the cells. Instead, the addition of the IPTG had no effect, as protein expression
either decreased or the protein began to degrade over time. It is not entirely clear why
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IPTG induction was not successful with this plasmid. In E. coli, the lac operon contains the
gene lacI, which expresses the lac repressor. The lac repressor binds to the lac operator
and inhibits transcription from moving to the promoter. When IPTG is added to E. coli,
expression is induced at the promoter (Hansen et al., 1998).
In an attempt to increase the expression of CRABP1 protein in these cells
transformed with the pBS crabp1 plasmid, glucose was added to the culture media. Glucose
is known to prevent “leaky” protein expression before induction (Novy and Morris, 2001).
Varying percentages of glucose were added (0%, 0.5%, 1% and 2%) to the cell cultures
prior to induction with IPTG. The addition of glucose did not appear to prevent expression
prior to induction. In fact, we observed a decrease in expression over the course of time,
regardless of the percentage of glucose added to the media (Figures 3 and 4). These results
were similar to that of the protein expression trials in the absence of glucose (Figure 2), in
that the expression seemed to decrease post-induction or there was protein degradation
over time.
Next, BL21(DE3) pLysS cells were used, again in an attempt to prevent preinduction expression of the protein. This was executed by transforming the pBS plasmid
with crabp1 into cells containing the pLysS plasmid. This plasmid expresses T7 lysozyme,
which inhibits the expression of inducible genes before IPTG induction. The pLysS
experiments were conducted by collecting samples pre-induction and three hours postinduction with IPTG. As observed in the previous trials, there was still expression before
induction and no visible increase in expression after induction. In fact, protein expression
seemed to decrease over time (Figure 5).
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Because we were unable to achieve inducible expression of the CRABP1 protein in
the pBS plasmid, our next step was to clone the gene into a different plasmid, which would
serve two aims: (1) achieve inducible protein expression and (2) add an affinity tag to the
protein, which would ultimately lead to more efficient purification. We had three
expression vectors available to us: pET15b, pRSF-1, and pET-Duet.
The crabp1 gene was first amplified using pET15b, pET-Duet and pRSF-1 specific
primers. Primer design took time and care, and this process had to be repeated after our
first attempt, as the crabp1 gene was not in-frame with the encoded purification tags on
our first attempt at primer design (data not shown). However, we were eventually able to
amplify crabp1 using appropriately designed primers for the plasmids we wanted to use.
Our attempts at digesting the different plasmids with our restriction enzymes of
interest were, in part, successful. The pRSF-1 and pET-15b plasmids had the most
successful digests, whereas the pET-Duet restriction digest did not work as well as seen by
the unconcentrated double band seen on the gel(Figure 8), possibly due to the use of an
older aliquot of the restriction enzyme. Once both the plasmids and crabp1 were digested
and gel-purified, we next attempted ligation.
The digested crabp1 insert was ligated with the digested plasmids. We attempted
these ligations many times using a variety of ratios of insert-to-plasmid. Additionally, we
tried varying lengths of time for these ligations and different aliquots of the ligase to see if
this would aid in successful ligation reactions. These ligations were transformed into
BL21(DE3) cells. The ligation only seemed to be successful using the pRSF-1 plasmid, as no
colonies grew on the plates with the pET-15b plasmid and insert. In addition, we also noted
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that the positive control plates had many colonies grow, while the negative control plates
had very few colonies.
Cells from the resulting pRSF-1 colonies were collected for colony PCR. The results
of the colony PCR for the pRSF-crabp1 colonies showed bands at the correct molecular
weight for crabp1 from all tested colonies except for the negative and positive controls.
Though the bands were faint, we grew up two of these colonies and performed minipreps
to get concentrated plasmid DNA. Our last experiments included testing the expression of
one of the pRSF-crabp1 plasmids, though we did not see overexpression of the CRABP1
protein in Coomassie gels (data not shown). Further tests with respect to these isolated
plasmids will include sequencing the plasmids and also performing a Western blot to see if
the CRABP1 protein is expressed.
Once the gene is successfully incorporated into an expression plasmid, the CRABP1
protein will then be purified. The protein will be overexpressed, the cells lysed using a
sonicator, and the lysate applied to a nickel resin that specifically binds to the His-tagged
protein. Additional purification steps may be necessary depending on the purity of the
protein, which can be assessed by running a Coomassie protein gel. Should we not have
efficient lysis of the cells, an alternative method for acquiring the CRABP1 protein is to use
a signal sequence to secrete CRABP1 from the cells. A signal sequence is an extension on
the N-terminus of a protein, which conveys to the cellular machinery where to be “sent”
(Martoglio,1998). Such a sequence could be used to secrete the protein into the periplasmic
space, which would allow for easier extraction from the bacterial cell.
Though we spent most of the time in the lab working on the subcloning of the
crabp1 gene into different plasmids, there are many experiments that we hope to pursue
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upon successful cloning and purification of the CRABP1 protein. The experiments that we
envision would first be to assess the protein’s folding using techniques that might include
circular dichroism or differential scanning fluorimetry. Non-bacterial proteins that are
expressed in these microorganisms are sometimes misfolded, and before testing CRABP1’s
ability to bind to ligands or inhibitors we would first want to make sure that it was folded.
The purpose of finding a small molecule to bind to CRABP1 would be to free up retinoic
acid. If, using a small molecule library, we could find a molecule that has a higher affinity to
CRABP1 than retinoic acid, retinoic acid would be freed up to accumulate in the adipose
stromal cells. The affinity of the small molecules to CRABP1 could be tested by using a
thermal shift assay. Lastly, we would make mutations to CRABP1 in order to find a
mutation that causes CRABP1 to have the inability to bind to retinoic acid. This would be
done by systematically mutating single amino acids within the binding pocket for retinoic
acid. Once a promising mutation is found, the mutated CRABP1 would be tested in the
adipose stromal cells to assess lipid accumulation.
Next, the purified and properly folded CRABP1 protein could be screened with a
small-molecule library to find small molecules that have a high affinity for CRABP1. It was
found in a previous study that CRABP1 prevents the accumulation of retinoic acid in
adipose stromal cells by binding to and sequestering it. The goal in this part of the
experiment would be to find small molecules that bind to CRABP1 and have a higher
affinity for CRABP1 than retinoic acid and CRABP1. The affinity of the small molecules to
CRABP1 could be tested via thermal shift assay or isothermal titration calorimetry (ITC).
Then, tests could be done with these molecules in vitro using techniques such as a lipid
accumulation assay to see whether the cells can regain the ability to accumulate lipids. It is
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hypothesized that CRABP1 would bind with a molecule that has a higher affinity, leaving
retinoic acid to be free to accumulate in the adipose stromal cells.
Lastly, we could attempt to mutate specific amino acids to see if any mutations cause
CRABP1 to have the inability to bind to retinoic acid. In a normal CRABP1 and retinoic acid
interaction, the hydrophobic β-sheets in the CRABP1 protein encase the hydrophobic tail
while the carboxylate head group of the retinoic acid hydrogen bonds to the polar amino
acids in the CRABP1. We could systematically make single mutations of amino acids,
specifically within the retinoic acid binding pocket of CRABP1, to determine if these
mutations cause a decrease in affinity between CRABP1 and retinoic acid. To do this, sitedirected mutagenesis could be used on the plasmid sequence followed by expression and
purification of the mutated CRABP1. We could then determine if the mutated protein is
folded correctly and test the affinity of retinoic acid to the mutated CRABP1 protein.
Finally, this protein could then be tested in ASC-Ls or other supporting cells to observe the
effectiveness of mutating the CRABP1 on lipid accumulation in adipose stromal cells.
Although this research leaves many open-ended questions about the relationship between
CRABP1 and pregnancy associated breast cancer and the specific role that it plays, these
questions have potential to encourage research to improve our understanding of this
complex disease.
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Figures and Captions
Plasmid
pBS
pRSF-1 Duet
pET-1 Duet
pET15b

Table 1.
Antibiotic Resistance
Ampicillin
Kanamycin
Ampicillin
Ampicillin

Restriction Enzymes
N/A
PstI and HindIII
EcoRI and HindIII
NDEI and BamHI

Table 1. This table shows the specific antibiotic resistances and restriction digest enzymes needed for all
plasmids used.

Figure 1. Structure of CRABP1 bound to retinoic acid. Image generated by WebGL Protein Viewer using the
atomic coordinates from PDB ID 1CBR.
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Figure 2. The expression of CRABP1 in BL21(DE3) cells. Lane 2 are uninduced cells, Lane 3 are
cells lysed 3 hours post-induction, Lane 4 are cells lysed 6 hours post-induction, and Lane 5 are
cells lysed after being left overnight post-induction.

Figures 3 and 4. The expression of CRABP1 in BL21(DE3) cells with the addition of glucose.
The lanes for both are as follows: (1) molecular weight ladder , (2) 0% glucose uninduced, (3) 0%
glucose 3 hours post-induction, (4) 0.5% glucose uninduced, (5) 0.5% glucose 3 hours postinduction, (6) 1% glucose uninduced, (7) 1% glucose 3 hours post-induction, (8) 2% glucose
uninduced, and (9) 2% glucose 3 hours post-induction. Figure 2 (left) shows the Coomassie stain of
all protein expression while Figure 3 (right) shows the expression of just the CRABP1 protein. For
both figures, all lanes show a noticeable decreased in expression from before to after induction.
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Figure 5. The Expression of CRABP1 in pBS with BL21 cells with the addition of pLysS
plasmid. Lane 1 contains the molecular weight marker, lane 2 contains the uninduced sample, and
lane 3 contains the 3-hour post-induction sample. There are discernable bands before and after
induction with little change in concentration of the bands.

Figure 6. PCR amplification of crabp1 using pET-15b- and pRSF-1-specific primers. Lanes 1
and 8 contain a 1kb ladder. Lanes 2-4 contain the amplified crabp1 using primers designed for the
pET15b plasmid. Lanes 5-7 contain the amplified crabp1 using primers specific for the pRSF-1
plasmid. Lanes 2-7 all show bright bands right below 500 base pairs corresponding to the crabp1
gene.
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Figure 7. PCR amplification of crabp1 using pET-Duet specific primers. Lanes 1 and 5 contain a
1kb ladder. Lanes 2-4 contain the amplified crabp1 using primers specific for the pET-Duet plasmid.
The most intense bands in lanes 2-4 are located below 500 base pairs, again corresponding to the
crabp1 gene.

Figure 8. Restriction digest of pET-Duet, pRSF-1 and crabp1 with EcoRI and HindIII. Lanes 1
and 8 contain a 1kb ladder. Lanes 2 and 3 contain the digested pET-Duet plasmid, lanes 4 and 5
contain the digested pRSF-1 plasmid and lanes 6 and 7 contain the digested crabp1.
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Figure 9. Restriction digest of pET-15b plasmid and crabp1. Lanes 1 and 6 contain 1kb ladders.
Lanes 2 and 3 contain the digested pET15b plasmid and lanes 4 and 5 contain the digested crabp1.

Figure 10. Restriction digest of pRSF-1 plasmid and crabp1.
Lanes 1 and 6 contain 1kb ladder, lanes 2 and 3 contain the digested pRSF-1 plasmid with bright
bands at about 4000 base pairs and faint bands between 4000 and 5000 base pairs. Lanes 4 and 5
contain the digested crabp1, with no discernable bands. Though no digested crabp1 is observed on
this gel, we were able to digest the gene is subsequent experiments to be utilized in ligation
reactions (data not shown).
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Figure 11. Restriction digest of crabp1 using pRSF-1 and pET-15b enzymes. Lanes 1 and 6
contain 1kb ladder, lanes 2 and 3 contain the digested crabp1 using the BamHI and NDEI restriction
enzymes and lanes 4 and 5 contain the digested crabp1 using HindIII and PstI.

Figure 12. Colony PCR of crabp1 ligation into pRSF-1. In the 8-well gel (left) lane 1 contains a
1kb ladder, lanes 2-4 contain 1:1 plasmid to insert ligation samples and lanes 5-7 contain 3:5
plasmid to insert ligation samples. In the 10-well gel (right), lane 1 contains a 1kb ladder, lanes 2-4
contain 1:7 ligation samples plasmid to insert, lane 8 contains a positive control and lane 9 contains
a negative control. There are faint bands below the 500 base-pair mark in lanes 2-7 of both gels.
Lanes 8 and 9 of the 10-well (right) gel do not show any bands.

